Elicio Therapeutics, Inc. (ELTX)

6.68 +0.06 (+0.91%) At close: 04:00PM EDT

Elicio Therapeutics, Inc.

451 D Street
5th Floor Suite 501
Boston, MA 02210
United States
857-209-0050
https://elicio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 32

Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Corporate governance

Elicio Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.